Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Narrative) (Details)

Revenues from Contracts and Significant Customers (Narrative) (Details) - Dermatology Products Sales - Customer Concentration Risk - customer	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Revenue
Disaggregation of Revenue [Line Items]
Number of customers	0	0
Accounts Receivable
Disaggregation of Revenue [Line Items]
Number of customers		2	2
Customer One \| Accounts Receivable
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		25.00%	16.70%
Customer Two \| Accounts Receivable
Disaggregation of Revenue [Line Items]
Concentration risk, percentage		15.00%	10.40%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details